Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cypress Bioscience purchases PRP:

This article was originally published in Clinica

Executive Summary

Cypress Bioscience (formerly Imre) is to acquire biopharmaceutical concern PRP, subject to shareholder approval and other conditions. Under the terms of the agreement, PRP will become a wholly-owned subsidiary of Cypress. Cypress, which is based in San Diego, manufactures medical devices and therapeutics for the treatment of certain immune disorders. Its leading product, the Prosorba column, is approved by the US FDA for use in the treatment of idiopathic thrombocytopenic purpura. The product is undergoing clinical trials for the treatment of rheumatoid arthritis. PRP produces agents to treat blood platelet disorders.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT088915

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel